Back to Search Start Over

Reduced-Intensity/Reduced-Toxicity Conditioning Approaches Are Tolerated in XIAP Deficiency but Patients Fare Poorly with Acute GVHD

Authors :
Emma C. Morris
Ashok Kumar
Justin T. Wahlstrom
Danielle E. Arnold
Connor Wakefield
Tim Brettig
Michael B. Jordan
Stephan Ehl
Theresa Cole
Jennifer Heimall
Małgorzata Salamonowicz
Michael H. Albert
Carsten Speckmann
Austen Worth
Rofida Nofal
Claire Booth
Nancy Bunin
Rebecca A. Marsh
Sharon Choo
Kai Lehmberg
Kanchan Rao
Katharina Wustrau
Source :
Journal of Clinical Immunology
Publication Year :
2021
Publisher :
Springer Science and Business Media LLC, 2021.

Abstract

X-linked inhibitor of apoptosis (XIAP) deficiency is an inherited primary immunodeficiency characterized by chronic inflammasome overactivity and associated with hemophagocytic lymphohistiocytosis (HLH) and inflammatory bowel disease (IBD). Allogeneic hematopoietic cell transplantation (HCT) with fully myeloablative conditioning may be curative but has been associated with poor outcomes. Reports of reduced-intensity conditioning (RIC) and reduced-toxicity conditioning (RTC) regimens suggest these approaches are well tolerated, but outcomes are not well established. Retrospective data were collected from an international cohort of 40 patients with XIAP deficiency who underwent HCT with RIC or RTC. Thirty-three (83%) patients had a history of HLH, and thirteen (33%) patients had IBD. Median age at HCT was 6.5 years. Grafts were from HLA-matched (n = 30, 75%) and HLA-mismatched (n = 10, 25%) donors. There were no cases of primary graft failure. Two (5%) patients experienced secondary graft failure, and three (8%) patients ultimately received a second HCT. Nine (23%) patients developed grade II–IV acute GVHD, and 3 (8%) developed extensive chronic GVHD. The estimated 2-year overall and event-free survival rates were 74% (CI 55–86%) and 64% (CI 46–77%), respectively. Recipient and donor HLA mismatch and grade II–IV acute GVHD were negatively associated with survival on multivariate analysis with hazard ratios of 5.8 (CI 1.5–23.3, p = 0.01) and 8.2 (CI 2.1–32.7, p

Details

ISSN :
15732592 and 02719142
Volume :
42
Database :
OpenAIRE
Journal :
Journal of Clinical Immunology
Accession number :
edsair.doi.dedup.....3accd2736eb2f8eab471afbfd90702a2